U
ALIM

UBS’s Alimera Sciences ALIM Stock Holding History

UBS’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-75
Closed -$6.41K – 10847
2014
Q2 		$7K Buy
+75
New +$6.66K ﹤0.01% 9260
2014
Q1 		– Sell
-264
Closed -$25.6K – 10902
2013
Q4 		$19K Sell
264
-129
-33% -$5.26K ﹤0.01% 8226
2013
Q3 		$22K Sell
393
-15
-4% -$941 ﹤0.01% 7954
2013
Q2 		$30K Buy
+408
New +$23.6K ﹤0.01% 7395

Other funds holding ALIM

PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS's ALIM Position: Q3 2014 in Review

UBS sold out of Alimera Sciences (ALIM) in Q3 2014, closing a stake of 75 shares — an estimated $6.41K sold.

UBS first reported a position in ALIM in Q2 2013 and held it in 4 quarters. The position peaked at $30K in Q2 2013. 60 funds tracked by Wall St. Rank hold ALIM as of Q3 2014.

  • UBS reported no remaining Alimera Sciences position as of Q3 2014 after selling out during the quarter.
  • UBS sold 75 Alimera Sciences shares in Q3 2014, an estimated $6.41K.
  • UBS first reported a position in Alimera Sciences in Q2 2013 and held it in 4 quarters.
  • UBS's Alimera Sciences position peaked at $30K in Q2 2013.
  • 60 funds tracked by Wall St. Rank held Alimera Sciences as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.